Stockscreener 앱 받기
0.9789
1.92%
0.0184
시간 외 거래:
.98
0.0011
+0.11%
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Oncolytics Biotech Shares Gain on Upcoming Clinical Data Presentations - AD HOC NEWS
Oncolytics Biotech® to Host Conference Call to Discuss Second Qu - GuruFocus
Oncolytics Biotech Showcases Pelareorep as Immune-Priming Backbone With New AACR 2026 Data - TipRanks
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - marketscreener.com
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - GlobeNewswire Inc.
Stocks in play: Oncolytics Biotech Inc - Barchart
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care - The Globe and Mail
Oncolytics (ONCY) Presents Promising Cancer Research at AACR 202 - GuruFocus
Oncolytics Highlights New Pelareorep Data in Cancer Immunotherapy - TipRanks
Oncolytics Biotech (Nasdaq: ONCY) showcases new pelareorep immune-priming data at AACR 2026 - Stock Titan
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 - The Spec
Oncolytics Biotech Inc. (ONCY) Competitors - Meyka
Is It Time To Reconsider Oncolytics Biotech (ONCY) After A Huge DCF Valuation Gap? - simplywall.st
Growth Report: What is Oncolytics Biotech Incs market position2026 Growth vs Value & Fast Entry Momentum Alerts - baoquankhu1.vn
Insider Buying: James Parsons Acquires Additional Shares of Onco - GuruFocus
Insider Buying: Oncolytics Biotech (NASDAQ:ONCY) Director Purchases 10,000 Shares of Stock - MarketBeat
Insider Buying: James Parsons Acquires Additional Shares of Oncolytics Biotech Inc (ONCY) - GuruFocus
Oncolytics Biotech (ONCY) director adds 10,000 common shares - Stock Titan
Oncolytics Biotech (ONCY) CEO buys 5,050 common shares at $0.96 - Stock Titan
ONCY Technical Analysis | Trend, Signals & Chart Patterns | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
ONCY SEC FilingsOncolytics Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
What is Oncolytics Biotech Incs 5 year growth outlookProduct Launch & Verified Swing Trading Watchlists - baoquankhu1.vn
How Oncolytics Biotech Inc. stock compares to market leadersProfit Target & Step-by-Step Swing Trade Plans - Naître et grandir
ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug - Stocktwits
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types - marketscreener.com
Oncolytics Biotech Advances Pelareorep Into New Phase 2 Colorectal Cancer Study - TipRanks
Cancer Treatment Breakthroughs Stack Up as Clinical Pipelines Advance - Baystreet.ca
Earnings Report: Is Oncolytics Biotech Inc undervalued by DCF analysisJuly 2025 Drop Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion - Cantech Letter
Oncolytics Biotech Launches Randomized Phase 2 REO-033 Trial for Pelareorep in RAS-Mutant MSS Metastatic Colorectal Cancer — With FDA Fast Track Behind It - Oncodaily
Oncolytics launches phase 2 colorectal cancer study REO 033 By Investing.com - Investing.com Canada
Oncolytics launches phase 2 colorectal cancer study REO 033 - Investing.com
Oncolytics Biotech Launches Phase 2 Colorectal Cancer Trial - TipRanks
Oncolytics Biotech Launches Randomized Colorectal Cancer Study - Bitget
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech (NASDAQ: ONCY) launches Phase 2 pelareorep colorectal cancer study - Stock Titan
Oncolytics Biotech Inc initiates phase 2 study for metastatic colorectal cancer - marketscreener.com
Oncolytics (ONCY) Initiates Phase 2 Trial for Metastatic Colorec - GuruFocus
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study - The Manila Times
Oncolytics Biotech Refocuses On Rare Cancers After GOBLET Enrollment Milestone - simplywall.st
Oncolytics Biotech Refocuses On Rare Cancers After GOBLET Milestone - Sahm
Oncolytics Biotech (ONCY) Expected to Announce Earnings on Friday - MarketBeat
Oncolytics Biotech rises as U.S. FDA clears path for pancreatic cancer trial - TradingView
Lake Street Sticks to Their Buy Rating for Oncolytics Biotech (ONCY) - The Globe and Mail
Oncolytics Biotech gains as enrollments for GIT cancer trial conclude - MSN
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 - Cantech Letter
Oncolytics to wind down GOBLET study, focus on U.S. registration - Investing.com India
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge - The Malaysian Reserve
Oncolytics Biotech (ONCY) Valuation Check After Recent Share Price Momentum And Conflicting Signals - Sahm
Death Cross: Will Oncolytics Biotech Inc outperform the market in YEARJuly 2025 Earnings & Short-Term Swing Trade Alerts - baoquankhu1.vn
Oncolytics Biotech (ONCY) Ends Enrollment in GOBLET Study to Foc - GuruFocus
Oncolytics to wind down GOBLET study, focus on U.S. registration By Investing.com - Investing.com Canada
Oncolytics to stop enrollments for GIT cancer trial (ONCY) - Seeking Alpha
Oncology Market Set to Nearly Triple: Here Are Five Companies Le - GuruFocus
Oncolytics (ONCY) Completes Enrollment in GOBLET Study, Advances Cancer Research - GuruFocus
Cancer Drug Market on Track to Double by 2033: Five Oncology Plays to Watch - Baystreet.ca
1.20%
0.06%
자본화:
|
볼륨(24시간):